<DOC>
	<DOC>NCT03002376</DOC>
	<brief_summary>This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.</brief_summary>
	<brief_title>An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirmed diagnosis of stage III (unresectable) or stage IV melanoma with at least 1 lesion that is measurable by RECIST 1.1 criteria and accessible for biopsies Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 Adequate hepatic function Adequate renal function Adequate bone marrow function Willing and able to comply with clinic visits and studyrelated procedures Provide signed informed consent Able to understand and complete studyrelated questionnaires Anticipated life expectancy &gt;12 week Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immunerelated adverse events (irAEs). Prior treatment with an agent that blocks the programmed death1/ programmed deathligand 1 (PD1/PDL1 pathway) Prior treatment with other immune modulating anticancer agents, except for remote treatment (&gt;6 months) in adjuvant setting. Untreated brain metastasis(es) that may be considered active. Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810 Other protocoldefined inclusion/exclusion criteria will apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>